Howard Sofen, M.D.
Dr. Howard Sofen is a dermatologist who is currently affiliated with Cedars-Sinai Marina del Rey Hospital. He received his medical degree from Drexel University College of Medicine and completed his residency at UCLA VA Wadsworth. With over 20 years of practice, he is certified by the American Board of Dermatology and he has the title of AAD Fellow. The medical professional has published numerous papers on dermatological issues and he specializes in diagnosing and treating a wide spectrum of hair, skin, and nail conditions. Dr. Howard Sofen has been Medical Director throughout Los Angeles since 1985. He graduated Cum Laude from UCLA, with a Bachelor of Science in Biochemistry. The dermatologist performed graduate work in Biology at UCLA before attending Hahnemann Medical College in Philadelphia, where he graduated with Honors in Pathology.
Dr. Howard Sofen is a Diplomate of the American Board of Dermatology and is serving as the Assistant Clinical Professor of Medicine at the UCLA School of Medicine at the moment. He is also a member of the National Psoriasis Foundation, the California Dermatology Society, and the National Eczema Association. Dr. Howard Sofen also acts as a primary investigator for clinical trials, testing new medicines for cutaneous conditions such as psoriasis and atopic dermatitis, and travels nationally to give lectures to other dermatologists concerning the treatment of skin conditions. He has served as an expert witness in numerous civil litigation, medical malpractice, and worker's compensation claims, having been a certified Qualified Medical Examiner, Agreed Medical Examiner, and Independent Medical Examiner since 1986.
- Aetna Choice POS II
- First Health PPO
- Great West PPO
- Multiplan PPO
- United Healthcare
Education & Training
Drexel University College of Medicine
University of Southern California - LAC+USC Medical Center
UCLA VA Wadsworth
US Department Of Veterans Affairs
Publications & Media
Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial.
Sofen, H., Hudson, C. P., Cook-Bolden, F. E., Preston, N., Colon, L. E., Caveney, S. W., Gottschalk, R. W.
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb, R. E., Blauvelt, A., Sofen, H. L., Chevrier, M., Amato, D., Calabro, S., Wang, J., Schenkel, B., Gottlieb, A. B.
A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Sofen, H., Gross, K. G., Goldberg, L. H., Sharata, H. H., Hamilton, T. K., Egbert, B. M., Lyons, B., Hou, J., Caro, I.
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E., Williams, N., Guana, A., Tyring, S.
An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis.
Hudson, C. P., Kempers, S., Menter, A., Papp, K., Smith, S., Sofen, H., Colón, L. E., Johnson, L. A., Gottschalk, R.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Kimball, A. B., Papp, K. A., Wasfi, Y., Chan, D., Bissonnette, R., Sofen, H., Yeilding, N., Li, S., Szapary, P., Gordon, K. B.
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Griffiths, C. E., Vender, R., Sofen, H., Kircik, L., Tan, H., Rottinghaus, S. T., Bachinsky, M., Mallbris, L., Mamolo, C.
Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.
Guenther, L., Han, C., Szapary, P., Schenkel, B., Poulin, Y., Bourcier, M., Ortonne, J. P., Sofen, H. L.
Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses.
Del Rosso, J. Q., Sofen, H., Leshin, B., Meng, T., Kulp, J., Levy, S.
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., Zook, M., Zammit, D. J., Usansky, H., Denis, L., Rao, N., Song, T., Pavel, A. B., Guttman-Yassky, E.
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis.
Gooderham, M., Elewski, B. E., Pariser, D. M., Sofen, H., Mendelsohn, A. M., Rozzo, S. J., Li, Q.
Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US.
Goldstein, S., Eftekhari, S., Mitchell, L., Winders, T. A., Kaufman, L., Dudas, D., Paknis, B., Kavati, A., Delwart, V., Sofen, H. L.
Treatment of generalised pustular psoriasis with isotretinoin.
Sofen, H. L., Moy, R. L., Lowe, N. J.